850363-42-7

Basic information

• Product Name: [1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: [1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER;tert-Butyl N-[1-(4-broMophenyl)ethyl]carbaMate;tert-butyl 1-(4-bromophenyl)ethylcarbamate
• CAS NO: 850363-42-7
• Molecular Formula: C₁₃H₁₈BrNO₂
• Molecular Weight: 300.19
• Mol File: 850363-42-7.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 383.1±25.0 °C(Predicted)
• Appearance: /
• Density: 1.282±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 11.94±0.46(Predicted)
• CAS DataBase Reference: [1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER(850363-42-7)
• EPA Substance Registry System: [1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER(850363-42-7)

Safety Data

• Hazardous Substances Data: 850363-42-7(Hazardous Substances Data)

Usage

General Description

"[1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER" is a chemical compound with the molecular formula C12H16BrNO2. It is an ester derivative of carbamic acid, with a tert-butyl group attached. The presence of a bromo-phenyl group in the structure suggests that this compound contains a benzene ring with a bromine atom attached to it. [1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER may have potential applications in the field of medicinal chemistry or organic synthesis, but its specific properties and uses would need to be further investigated through scientific study.

Upstream product

• 110-05-4 di-tert-butyl peroxide 
• 68819-84-1 tert-butyl N-(4-bromobenzyl)carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 24358-62-1 1-(4-bromophenyl)ethylamine 
• 90006-14-7 (S)-1-(4-bromophenyl)ethanamine hydrochloride 

Downstream Products

• 1428526-28-6 diethyl (4-{1-[(tert-butoxycarbonyl)amino]ethyl}phosphonate) 
• 1428526-34-4 ethyl hydrogen 4-(1-(4-hydroxy-2-(pyridin-2-yl)pyrimidine-5-carboxamido)ethyl)phenylphosphonate 
• 1428526-33-3 4-(1-(4-hydroxy-2-(pyridin-2-yl)pyrimidine-5-carboxamido)ethyl)phenylphosphonic acid 
• 1428526-32-2 diethyl 4-(1-(4-hydroxy-2-(pyridin-2-yl)pyrimidine-5-carboxamido)ethyl)phenylphosphonate 
• 1428526-29-7 diethyl 4-(1-aminoethyl)phenylphosphonate hydrochloride 
• 1428526-81-1 4-(1-(4-hydroxy-2-(1H-pyrazol-1-yl)pyrimidine-5-carboxamido)ethyl)phenylphosphonic acid 
• 1428526-80-0 C₁₄H₂₈NO₃PSi₂ 
• 1241910-32-6 2-methyl-N-(1-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)ethyl)-1,8-naphthyridine-3-carboxamide 
• 1241911-38-5 tert-butyl 1-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)ethylcarbamate 
• 1241911-37-4 tert-butyl 1-(4-(2,2,2-trifluoro-1-(tosyloxyimino)ethyl)phenyl)ethylcarbamate 
• 1241911-36-3 tert-butyl 1-(4-(2,2,2-trifluoro-1-(hydroxyimino)ethyl)phenyl)ethylcarbamate 
• 1015422-73-7 tert-butyl N-{1-[4-(1-hydroxyethyl)phenyl]ethyl}carbamate 
• 895577-21-6 4-(1-tert-butoxycarbonylamino-ethyl)benzoic acid 
• 1241911-35-2 tert-butyl 1-(4-(2,2,2-trifluoroacetyl)phenyl)ethylcarbamate 

Relevant articles and documents

C(sp3)-H methylation enabled by peroxide photosensitization and Ni-mediated radical coupling

The “magic methyl” effect describes the change in potency, selectivity, and/or metabolic stability of a drug candidate associated with addition of a single methyl group. We report a synthetic method that enables direct methylation of C(sp3)-H bonds in diverse drug-like molecules and pharmaceutical building blocks. Visible light-initiated triplet energy transfer promotes homolysis of the O-O bond in di-tert-butyl or dicumyl peroxide under mild conditions. The resulting alkoxyl radicals undergo divergent reactivity, either hydrogen-atom transfer from a substrate C-H bond or generation of a methyl radical via b-methyl scission. The relative rates of these steps may be tuned by varying the reaction conditions or peroxide substituents to optimize the yield of methylated product arising from nickel-mediated cross-coupling of substrate and methyl radicals.

ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

A compound of formula (I): wherein the substituents are as defined in the description. Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the RhoA/ROCK pathway and phosphorylation of the myosin light chain.

SUBSTITUTED PYRIMIDINES

The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.